Clinical Trial News and Research

RSS

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

29 Oct 2010

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

StemCells, Inc. announced today that it has initiated a second clinical trial of its HuCNS-SC product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease), a fatal neurodegenerative disorder in children.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended September 30, 2010.

29 Oct 2010

CCS presents new 2010 Atrial Fibrillation Guidelines

The Canadian Cardiovascular Society (CCS) presented its new 2010 Atrial Fibrillation Guidelines, the first update in six years, at the Canadian Cardiovascular Congress (CCC) in Montreal.

28 Oct 2010

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

Pfizer Inc. announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the October 28 issue of the New England Journal of Medicine.

28 Oct 2010

Curemark adds two sites in California for CM-AT Phase III clinical trial program

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that it has added two sites in California to its Phase III clinical trial program for CM-AT, the company's autism treatment.

28 Oct 2010

Cell Therapeutics 2010 third quarter total net operating expense decreases 52% to $13.0 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the third quarter ended September 30, 2010.

28 Oct 2010

Reuters examines development progress of microbicide gel to prevent HIV

Reuters reports that the developers of a vaginal microbicide gel containing the antiretroviral tenofovir, which has been found to reduce "HIV infections in women by 39 percent," said the FDA last week granted fast-track approval designation to the gel.

28 Oct 2010

Endologix announces definitive agreement to acquire Nellix

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has signed a definitive agreement to acquire Nellix, Inc, a privately-held medical device company that has developed a revolutionary endograft for the treatment of Abdominal Aortic Aneurysms (AAAs).

28 Oct 2010

InVivo Therapeutics completes reverse merger with InVivo

InVivo Therapeutics Corporation a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced the successful completion of a reverse merger with InVivo Therapeutics Holdings Corp.

28 Oct 2010

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that it received approval from the State Food and Drug Administration ("SFDA") Ethics Committee to commence Phase I human clinical trials of R-Bambuterol Hydrochloride, the Company's proprietary drug candidate for the treatment of asthma.

28 Oct 2010

Endologix 2010 third quarter total revenue increases 30% to $17.9 million

Endologix, Inc. developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2010.

28 Oct 2010

Viropharma 2010 third quarter net sales increases 46% to $317.4 million

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2010.

27 Oct 2010

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained an initial draft report of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON (OX1).

27 Oct 2010

Survey shows Americans are unaware about causes of lung cancer

Men and women worry about prostate and breast cancer, yet the number one cancer killer in the United States – lung cancer – isn't on their radar. According to a survey released today by the National Lung Cancer Partnership, Americans know little about lung cancer's causes, symptoms and the number of lives it takes compared to other cancers.

27 Oct 2010

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan Corporation, plc today reported its third quarter and first nine months 2010 financial results.

27 Oct 2010

HIFU technology effective for treating metastatic liver cancer

EDAP TMS SA the global leader in therapeutic ultrasound, reported today successful completion of the first phase of the clinical protocol aimed at evaluating High Intensity Focused Ultrasound (HIFU) technology in patients with metastatic liver cancer. HIFU has the potential to destroy liver tumors through ablation and to reduce bleeding during surgery.

27 Oct 2010

Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain

Oncolytics Biotech Inc. announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain.

27 Oct 2010

PPD and VirtualScopics partner to provide medical imaging services

PPD, Inc. and VirtualScopics, Inc. today announced a strategic alliance to deliver a comprehensive set of clinical and medical imaging services that will enable biopharmaceutical companies to make faster, more confident decisions on the development of their oncology compounds, creating time and cost efficiencies.

26 Oct 2010